Intrinsic value of Lannett - LCI

Previous Close

$13.50

  Intrinsic Value

$32.93

stock screener

  Rating & Target

str. buy

+144%

Previous close

$13.50

 
Intrinsic value

$32.93

 
Up/down potential

+144%

 
Rating

str. buy

We calculate the intrinsic value of LCI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  16.80
  15.62
  14.56
  13.60
  12.74
  11.97
  11.27
  10.64
  10.08
  9.57
  9.11
  8.70
  8.33
  8.00
  7.70
  7.43
  7.19
  6.97
  6.77
  6.59
  6.43
  6.29
  6.16
  6.05
  5.94
  5.85
  5.76
  5.69
  5.62
  5.56
Revenue, $m
  739
  855
  979
  1,112
  1,254
  1,404
  1,563
  1,729
  1,903
  2,085
  2,275
  2,473
  2,680
  2,894
  3,117
  3,348
  3,589
  3,839
  4,099
  4,369
  4,650
  4,943
  5,248
  5,565
  5,895
  6,240
  6,600
  6,975
  7,367
  7,776
Variable operating expenses, $m
  548
  621
  700
  784
  874
  969
  1,070
  1,175
  1,285
  1,401
  1,442
  1,568
  1,698
  1,834
  1,975
  2,122
  2,274
  2,433
  2,598
  2,769
  2,947
  3,132
  3,325
  3,527
  3,736
  3,955
  4,182
  4,420
  4,669
  4,928
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  548
  621
  700
  784
  874
  969
  1,070
  1,175
  1,285
  1,401
  1,442
  1,568
  1,698
  1,834
  1,975
  2,122
  2,274
  2,433
  2,598
  2,769
  2,947
  3,132
  3,325
  3,527
  3,736
  3,955
  4,182
  4,420
  4,669
  4,928
Operating income, $m
  192
  234
  279
  328
  380
  435
  493
  554
  618
  685
  833
  906
  981
  1,060
  1,142
  1,226
  1,315
  1,406
  1,501
  1,600
  1,703
  1,810
  1,922
  2,038
  2,159
  2,286
  2,417
  2,555
  2,698
  2,848
EBITDA, $m
  397
  459
  526
  597
  673
  754
  839
  928
  1,022
  1,120
  1,222
  1,328
  1,439
  1,554
  1,674
  1,798
  1,927
  2,061
  2,201
  2,346
  2,497
  2,654
  2,818
  2,988
  3,166
  3,351
  3,544
  3,745
  3,956
  4,176
Interest expense (income), $m
  67
  82
  98
  115
  134
  154
  175
  198
  221
  246
  272
  300
  328
  358
  389
  421
  454
  489
  525
  562
  601
  642
  684
  728
  773
  821
  870
  922
  976
  1,032
  1,091
Earnings before tax, $m
  109
  136
  164
  194
  226
  260
  295
  333
  372
  412
  534
  578
  624
  671
  721
  772
  826
  881
  939
  999
  1,062
  1,127
  1,194
  1,265
  1,339
  1,415
  1,495
  1,579
  1,666
  1,758
Tax expense, $m
  30
  37
  44
  52
  61
  70
  80
  90
  100
  111
  144
  156
  168
  181
  195
  209
  223
  238
  254
  270
  287
  304
  323
  342
  361
  382
  404
  426
  450
  475
Net income, $m
  80
  99
  120
  142
  165
  190
  216
  243
  271
  301
  390
  422
  455
  490
  526
  564
  603
  643
  686
  729
  775
  823
  872
  924
  977
  1,033
  1,092
  1,153
  1,216
  1,283

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,872
  2,164
  2,479
  2,816
  3,175
  3,555
  3,956
  4,377
  4,818
  5,279
  5,761
  6,262
  6,784
  7,326
  7,891
  8,477
  9,086
  9,719
  10,377
  11,061
  11,773
  12,514
  13,285
  14,088
  14,925
  15,798
  16,708
  17,658
  18,650
  19,686
Adjusted assets (=assets-cash), $m
  1,872
  2,164
  2,479
  2,816
  3,175
  3,555
  3,956
  4,377
  4,818
  5,279
  5,761
  6,262
  6,784
  7,326
  7,891
  8,477
  9,086
  9,719
  10,377
  11,061
  11,773
  12,514
  13,285
  14,088
  14,925
  15,798
  16,708
  17,658
  18,650
  19,686
Revenue / Adjusted assets
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
  0.395
Average production assets, $m
  1,262
  1,459
  1,672
  1,899
  2,141
  2,397
  2,667
  2,951
  3,249
  3,560
  3,884
  4,222
  4,574
  4,940
  5,320
  5,716
  6,126
  6,553
  6,997
  7,458
  7,938
  8,438
  8,958
  9,499
  10,063
  10,652
  11,266
  11,906
  12,575
  13,274
Working capital, $m
  35
  41
  47
  53
  60
  67
  75
  83
  91
  100
  109
  119
  129
  139
  150
  161
  172
  184
  197
  210
  223
  237
  252
  267
  283
  300
  317
  335
  354
  373
Total debt, $m
  1,078
  1,268
  1,473
  1,692
  1,925
  2,172
  2,433
  2,706
  2,993
  3,293
  3,606
  3,932
  4,271
  4,624
  4,990
  5,371
  5,767
  6,179
  6,606
  7,051
  7,514
  7,995
  8,497
  9,019
  9,563
  10,130
  10,722
  11,339
  11,984
  12,657
Total liabilities, $m
  1,217
  1,407
  1,611
  1,831
  2,064
  2,311
  2,571
  2,845
  3,132
  3,432
  3,744
  4,070
  4,409
  4,762
  5,129
  5,510
  5,906
  6,317
  6,745
  7,190
  7,653
  8,134
  8,635
  9,157
  9,701
  10,269
  10,860
  11,478
  12,123
  12,796
Total equity, $m
  655
  757
  868
  986
  1,111
  1,244
  1,385
  1,532
  1,686
  1,848
  2,016
  2,192
  2,374
  2,564
  2,762
  2,967
  3,180
  3,402
  3,632
  3,871
  4,121
  4,380
  4,650
  4,931
  5,224
  5,529
  5,848
  6,180
  6,528
  6,890
Total liabilities and equity, $m
  1,872
  2,164
  2,479
  2,817
  3,175
  3,555
  3,956
  4,377
  4,818
  5,280
  5,760
  6,262
  6,783
  7,326
  7,891
  8,477
  9,086
  9,719
  10,377
  11,061
  11,774
  12,514
  13,285
  14,088
  14,925
  15,798
  16,708
  17,658
  18,651
  19,686
Debt-to-equity ratio
  1.650
  1.670
  1.700
  1.720
  1.730
  1.750
  1.760
  1.770
  1.770
  1.780
  1.790
  1.790
  1.800
  1.800
  1.810
  1.810
  1.810
  1.820
  1.820
  1.820
  1.820
  1.830
  1.830
  1.830
  1.830
  1.830
  1.830
  1.830
  1.840
  1.840
Adjusted equity ratio
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  80
  99
  120
  142
  165
  190
  216
  243
  271
  301
  390
  422
  455
  490
  526
  564
  603
  643
  686
  729
  775
  823
  872
  924
  977
  1,033
  1,092
  1,153
  1,216
  1,283
Depreciation, amort., depletion, $m
  206
  225
  246
  269
  293
  319
  346
  374
  404
  435
  388
  422
  457
  494
  532
  572
  613
  655
  700
  746
  794
  844
  896
  950
  1,006
  1,065
  1,127
  1,191
  1,258
  1,327
Funds from operations, $m
  285
  324
  366
  411
  458
  509
  562
  617
  675
  736
  778
  844
  913
  984
  1,058
  1,135
  1,215
  1,299
  1,385
  1,475
  1,569
  1,666
  1,768
  1,873
  1,984
  2,098
  2,218
  2,343
  2,474
  2,610
Change in working capital, $m
  5
  6
  6
  6
  7
  7
  8
  8
  8
  9
  9
  10
  10
  10
  11
  11
  12
  12
  12
  13
  13
  14
  15
  15
  16
  17
  17
  18
  19
  20
Cash from operations, $m
  280
  319
  360
  405
  452
  502
  554
  609
  667
  727
  769
  835
  903
  974
  1,048
  1,124
  1,204
  1,287
  1,373
  1,462
  1,555
  1,652
  1,753
  1,858
  1,968
  2,082
  2,201
  2,325
  2,455
  2,591
Maintenance CAPEX, $m
  -108
  -126
  -146
  -167
  -190
  -214
  -240
  -267
  -295
  -325
  -356
  -388
  -422
  -457
  -494
  -532
  -572
  -613
  -655
  -700
  -746
  -794
  -844
  -896
  -950
  -1,006
  -1,065
  -1,127
  -1,191
  -1,258
New CAPEX, $m
  -181
  -197
  -212
  -227
  -242
  -256
  -270
  -284
  -297
  -311
  -324
  -338
  -352
  -366
  -380
  -395
  -411
  -427
  -444
  -461
  -480
  -499
  -520
  -542
  -564
  -588
  -614
  -641
  -669
  -699
Cash from investing activities, $m
  -289
  -323
  -358
  -394
  -432
  -470
  -510
  -551
  -592
  -636
  -680
  -726
  -774
  -823
  -874
  -927
  -983
  -1,040
  -1,099
  -1,161
  -1,226
  -1,293
  -1,364
  -1,438
  -1,514
  -1,594
  -1,679
  -1,768
  -1,860
  -1,957
Free cash flow, $m
  -9
  -5
  2
  10
  20
  31
  44
  59
  74
  92
  89
  108
  129
  150
  173
  197
  222
  247
  274
  301
  330
  359
  389
  421
  453
  487
  522
  558
  596
  635
Issuance/(repayment) of debt, $m
  174
  190
  205
  219
  233
  247
  260
  274
  287
  300
  313
  326
  339
  353
  367
  381
  396
  412
  428
  445
  463
  481
  501
  522
  544
  567
  592
  618
  645
  674
Issuance/(repurchase) of shares, $m
  14
  3
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  188
  193
  205
  219
  233
  247
  260
  274
  287
  300
  313
  326
  339
  353
  367
  381
  396
  412
  428
  445
  463
  481
  501
  522
  544
  567
  592
  618
  645
  674
Total cash flow (excl. dividends), $m
  180
  189
  207
  229
  253
  278
  305
  332
  361
  391
  401
  434
  468
  503
  540
  578
  618
  659
  701
  746
  792
  840
  891
  943
  997
  1,054
  1,114
  1,176
  1,240
  1,308
Retained Cash Flow (-), $m
  -94
  -102
  -110
  -118
  -126
  -133
  -140
  -147
  -154
  -161
  -168
  -175
  -183
  -190
  -197
  -205
  -213
  -222
  -230
  -239
  -249
  -259
  -270
  -281
  -293
  -305
  -319
  -333
  -347
  -363
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  8
  9
  10
  12
  13
  15
  17
  19
  21
  23
  25
  27
  30
  32
  35
  37
  40
  43
  46
  49
  52
  56
  59
  63
  67
  71
  75
  79
  84
  88
Cash available for distribution, $m
  86
  86
  96
  111
  127
  145
  164
  185
  207
  230
  233
  258
  285
  313
  342
  373
  404
  437
  471
  506
  543
  581
  621
  662
  705
  749
  795
  843
  893
  946
Discount rate, %
  7.40
  7.77
  8.16
  8.57
  8.99
  9.44
  9.92
  10.41
  10.93
  11.48
  12.05
  12.66
  13.29
  13.95
  14.65
  15.38
  16.15
  16.96
  17.81
  18.70
  19.63
  20.62
  21.65
  22.73
  23.87
  25.06
  26.31
  27.63
  29.01
  30.46
PV of cash for distribution, $m
  80
  74
  76
  80
  83
  84
  85
  84
  81
  78
  67
  62
  56
  50
  44
  38
  32
  26
  21
  16
  13
  9
  7
  5
  3
  2
  1
  1
  1
  0
Current shareholders' claim on cash, %
  97.2
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7
  96.7

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

FINANCIAL RATIOS  of  Lannett (LCI)

Valuation Ratios
P/E Ratio -498.4
Price to Sales 0.8
Price to Book 0.9
Price to Tangible Book
Price to Cash Flow 3
Price to Free Cash Flow 4.3
Growth Rates
Sales Growth Rate 12.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 104.2%
Cap. Spend. - 3 Yr. Gr. Rate 13.5%
Financial Strength
Quick Ratio 2
Current Ratio 0.2
LT Debt to Equity 150.4%
Total Debt to Equity 161.1%
Interest Coverage 1
Management Effectiveness
Return On Assets -4%
Ret/ On Assets - 3 Yr. Avg. 12.8%
Return On Total Capital -0.1%
Ret/ On T. Cap. - 3 Yr. Avg. 14.6%
Return On Equity -0.2%
Return On Equity - 3 Yr. Avg. 16.1%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 47.9%
Gross Margin - 3 Yr. Avg. 59.3%
EBITDA Margin 19.3%
EBITDA Margin - 3 Yr. Avg. 34.2%
Operating Margin 13.5%
Oper. Margin - 3 Yr. Avg. 30.6%
Pre-Tax Margin 0.2%
Pre-Tax Margin - 3 Yr. Avg. 22.3%
Net Profit Margin -0.2%
Net Profit Margin - 3 Yr. Avg. 14.9%
Effective Tax Rate 200%
Eff/ Tax Rate - 3 Yr. Avg. 87.1%
Payout Ratio 0%

LCI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the LCI stock intrinsic value calculation we used $633 million for the last fiscal year's total revenue generated by Lannett. The default revenue input number comes from 2017 income statement of Lannett. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our LCI stock valuation model: a) initial revenue growth rate of 16.8% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7.4%, whose default value for LCI is calculated based on our internal credit rating of Lannett, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Lannett.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of LCI stock the variable cost ratio is equal to 75.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for LCI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.1% for Lannett.

Corporate tax rate of 27% is the nominal tax rate for Lannett. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the LCI stock is equal to 1.2%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for LCI are equal to 170.7%.

Life of production assets of 10 years is the average useful life of capital assets used in Lannett operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for LCI is equal to 4.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $561 million for Lannett - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 37 million for Lannett is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Lannett at the current share price and the inputted number of shares is $0.5 billion.

RELATED COMPANIES Price Int.Val. Rating
PFE Pfizer 42.09 24.58  sell
ABBV AbbVie 98.81 93.18  hold
CAH Cardinal Healt 51.90 169.21  str.buy
ABC AmerisourceBer 87.72 199.01  str.buy
MCK McKesson 129.38 355.02  str.buy
NVS Novartis ADR 83.04 59.65  sell
DPLO Diplomat Pharm 19.05 18.22  hold
JNJ Johnson&Johnso 134.47 126.96  hold
ANIP ANI Pharmaceut 56.41 27.39  str.sell

COMPANY NEWS

▶ Lannett Announces Multiple Product Launches   [Jul-23-18 06:53AM  PR Newswire]
▶ Lannett sells 2 buildings in Northeast Phila.   [Jul-18-18 01:42PM  American City Business Journals]
▶ 3 Top Healthcare Stocks to Buy Right Now   [Jun-28-18 08:51AM  Motley Fool]
▶ Benzinga Pro's 5 Stocks To Watch Today   [Jun-01-18 09:07AM  Benzinga]
▶ Lannett Receives FDA Approval For Dronabinol Capsules   [May-21-18 06:53AM  PR Newswire]
▶ Lannett: Fiscal 3Q Earnings Snapshot   [May-07-18 05:21PM  Associated Press]
▶ Lannett acquires 23 generic drug products from Endo subsidiary   [01:47PM  American City Business Journals]
▶ Edited Transcript of LCI presentation 6-Mar-17 7:50pm GMT   [Apr-10-18 04:47PM  Thomson Reuters StreetEvents]
▶ Lannett Strengthens, Augments Management Team   [Mar-23-18 06:53AM  PR Newswire]
▶ Hat trick: Lannett enters into 3 product agreements   [Mar-12-18 09:01AM  American City Business Journals]
▶ Why Lannett Company, Inc. Is Falling Today   [Feb-08-18 04:31PM  Motley Fool]
▶ Lannett beats 2Q profit forecasts   [Feb-07-18 07:01PM  Associated Press]
▶ Lannett Names Timothy C. Crew To Board Of Directors   [Jan-18-18 06:53AM  PR Newswire]
▶ Stocks Showing Improved Relative Strength: Lannett   [Jan-11-18 03:00AM  Investor's Business Daily]
▶ Stocks Generating Improved Relative Strength: Lannett   [Jan-04-18 03:00AM  Investor's Business Daily]
▶ Lannett names new CEO   [Dec-21-17 09:00AM  American City Business Journals]
▶ Lannett Appoints Timothy C. Crew As CEO   [06:54AM  PR Newswire]
▶ Lannett Shows Market Leadership With Jump To 94 RS Rating   [Dec-04-17 03:00AM  Investor's Business Daily]
▶ Lannett Joins Elite Club Of Stocks With RS Ratings Over 90   [03:00AM  Investor's Business Daily]
▶ Lannett beats Street 1Q forecasts   [Nov-06-17 06:45PM  Associated Press]
▶ Lannett Comments On Amended Civil Complaint   [Nov-01-17 06:53AM  PR Newswire]
▶ Lannett works out a deal with Celgene   [10:40AM  American City Business Journals]
▶ ETFs with exposure to Lannett Co., Inc. : October 9, 2017   [Oct-09-17 11:44AM  Capital Cube]
▶ Lannett's Board Of Directors Initiates CEO Search   [Sep-25-17 06:54AM  PR Newswire]
▶ What Is Lannett Company Incs (LCI) Share Price Doing?   [Sep-06-17 05:02PM  Simply Wall St.]
▶ Lannett receives FDA OK for generic Nexium product   [Sep-05-17 03:30PM  American City Business Journals]
▶ Lannett posts 4Q profit   [Aug-23-17 09:46PM  Associated Press]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.